scholarly journals 68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 622
Author(s):  
Finn Edler von Eyben ◽  
Cigdem Soydal ◽  
Rie von Eyben
Keyword(s):  
Cox Regression ◽  
External Beam Radiotherapy ◽  
Ct Scans ◽  
External Beam ◽  
Regression Analyses ◽  
Psa Relapse ◽  
Psma Pet ◽  
Pet Ct ◽  
Positive Site ◽  
Pet Ct Scan

The study aimed to summarize clinical characteristics associated with Gallium-68-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (68Ga-PSMA PET/CT) scans as patients were restaged for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or external beam radiotherapy (EBRT). Our analyses included multiple cox regression analyses. The study evaluated 95 patients with rising values of PSAs after RP and after EBRT. Sixty 63% of patients had a positive 68Ga-PSMA PET/CT scan. Twelve patients (13%) had a positive site in the prostate bed, 29 patients (30%) had a positive site in the regional lymph nodes, and 19 (20%) had positive sites in distant organs. After four years follow-up, 21 patients (22%) died. Using multiple Cox regression analyses, the number of positive sites on the 68Ga-PSMA PET/CT scan significantly predicted overall survival (OS) (p = 0.0001), whereas risk score and regional locations of the positive sites were not significant in the multiple Cox regression analyses. Our study indicates that the specific findings of 68Ga-PSMA PET/CT scans are important because detailed findings of the scans predict the outcome after salvage treatment of patients with PSA relapse examined with 68Ga-PSMA PET/CT scans.

18F-FDG-PET/CT guided external beam radiotherapy volumes in inoperable uterine cervical cancer

2018 ◽  
Vol 62 (4) ◽  
Author(s):  
Judit A. Adam ◽  
Hester Arkies ◽  
Karel Hinnen ◽  
Lukas J. Stalpers ◽  
Jan H. van Waesberghe ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Fdg Pet ◽  
External Beam Radiotherapy ◽  
Uterine Cervical Cancer ◽  
External Beam ◽  
Ct Guided ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

False Positive Uptake in Bilateral Gynecomastia on 68Ga-PSMA PET/CT Scan

2017 ◽  
Vol 42 (9) ◽  
pp. e412-e414 ◽  
Author(s):  
Arun Sasikumar ◽  
Ajith Joy ◽  
Bindu P. Nair ◽  
M.R. A. Pillai ◽  
Jayaprakash Madhavan
Keyword(s):  
Ct Scan ◽  
False Positive ◽  
Psma Pet ◽  
Pet Ct ◽  
Pet Ct Scan

scholarly journals Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Naresh Regula ◽  
Vasileios Kostaras ◽  
Silvia Johansson ◽  
Carlos Trampal ◽  
Elin Lindström ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Anatomical Location ◽  
Curative Therapy ◽  
Psa Relapse ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Relapse ◽  
Identical Number

AbstractPositron emission tomography (PET) imaging is used to localize recurrent disease in prostate cancer (PCa). The tracer 68Ga-PSMA-11 visualizes lesions overexpressing prostate-specific membrane antigen (PSMA), while 11C-acetate visualizes lesions with increased anabolic metabolism. The aim of this study was to compare the performance of PSMA-PET and acetate-PET in re-staging patients with biochemical relapse. Thirty PCa patients with prostate-specific antigen (PSA) relapse after primary curative therapy were prospectively evaluated. PET/CT examinations using 11C-acetate and 68Ga-PSMA-11 were performed. Identified lesions were categorized according to anatomical location and PET measurements were correlated with PSA at time of scan. Tumour lesions showed higher semi-quantitative uptake values on PSMA-PET than acetate-PET. PSMA-PET identified more lesions in 11 patients, fewer lesions in eight patients, and identical number of lesions in 11 patients. This study indicates better diagnostic performance of PSMA-PET, particularly in detecting lymph node (81% vs 60%, p = 0.02) and bone metastasis (95% vs 61%, p = 0.0001) compared to acetate-PET. However, 38% of PSMA-expressing metastases appear to be metabolically inactive and 15% of metabolically active metastases lack PSMA expression. Addition of PET with a metabolic tracer, such as 11C-acetate, might be beneficial before making treatment decisions.

scholarly journals Metastatic-directed therapy using PSMA-PET/CT at PSA relapse

2019 ◽  
Vol 27 ◽  
pp. 100992 ◽  
Author(s):  
Oscar Lilleby ◽  
Eivor Hernes ◽  
Wolfgang Lilleby
Keyword(s):  
Psa Relapse ◽  
Psma Pet ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document